Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 3 2Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 383Carcinoma, Renal Cell 210Urinary Bladder Neoplasms 117Carcinoma, Non-Small-Cell Lung 99Melanoma 78Kidney Neoplasms 74Carcinoma, Transitional Cell 73Neoplasm Metastasis 72Ovarian Neoplasms 71Breast Neoplasms 69Neoplasms 64Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 50Stomach Neoplasms 49Uterine Cervical Neoplasms 44Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 39Lung Neoplasms 35Esophageal Neoplasms 32Non-Muscle Invasive Bladder Neoplasms 31Endometrial Neoplasms 30Carcinoma, Hepatocellular 29Sarcoma 28Small Cell Lung Carcinoma 25Head and Neck Neoplasms 25Colonic Neoplasms 19Wilms Tumor 15Metastatic Castration-resistant Prostate Cancer 14Glioblastoma 14Carcinoma, Merkel Cell 14

Interventions

gossypol acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT00477529 2019-11-22

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Celgene

Phase 1/2 Completed
102 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00928252 2017-08-14

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Queen's Medical Center

Phase 1/2 Completed
25 enrolled 9 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00906243 2012-04-04

RNActive®-Derived Therapeutic Vaccine

University of Florida

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Ascenta Therapeutics

Phase 1/2 Completed
27 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡